Literature DB >> 26680137

Prehospital interventions in severely injured pediatric patients: Rethinking the ABCs.

Kyle K Sokol1, George E Black, Kenneth S Azarow, William Long, Matthew J Martin, Matthew J Eckert.   

Abstract

BACKGROUND: The current conflict in Afghanistan has resulted in a high volume of significantly injured pediatric patients. The austere environment has demanded emphasis on prehospital interventions (PHIs) to sustain casualties during transport.
METHODS: The Department of Defense Trauma Registry was queried for all pediatric patients (≤18 years) treated at Camp Bastion from 2004 to 2012. PHIs were grouped by Advanced Trauma Life Support categories into (1) airway (A)--intubation or surgical airway; 2) breathing (B)--chest tube or needle thoracostomy; and 3) circulation (C)--tourniquet or hemostatic dressing. Outcomes were assessed based on injury severity, hemodynamics, blood products and fluids, as well as mortality rates.
RESULTS: There were 766 injured children identified with 20% requiring one or more PHIs, most commonly circulation (C, 51%) followed by airway (A, 40%) and breathing (B, 8.7%). The majority of C interventions were tourniquets (85%) and hemostatic dressings (15%). Only 38% of patients with extremity vascular injury or amputation received a C intervention, with a significant reduction in blood products and intravenous fluids associated with receiving a C PHI (both p < 0.05). A interventions consisted of endotracheal intubation for depressed mental status (Glasgow Coma Scale [GCS] score < 8). Among patients with traumatic brain injury, A interventions were associated with higher unadjusted mortality (56% vs. 20%, p < 0.01) and remained independently associated with increased mortality after multivariate adjustment (odds ratio, 5.9; p = 0.001). B interventions were uncommon and performed in only 2% of patients with no recorded adverse outcomes.
CONCLUSION: There is a high incidence of PHIs among pediatric patients with severe wartime injuries. The most common and effective were C PHI for hemorrhage control, which should remain a primary focus of equipment and training. A interventions were most commonly performed in the setting of severe traumatic brain injury but were associated with worse outcomes. B interventions seem safe and effective and may be underused. LEVEL OF EVIDENCE: Care management/therapeutic study, level IV.

Entities:  

Mesh:

Year:  2015        PMID: 26680137     DOI: 10.1097/TA.0000000000000706

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  4 in total

1.  [Prehospital application of tourniquets for life-threatening extremity hemorrhage : Systematic review of literature].

Authors:  B Hossfeld; R Lechner; F Josse; M Bernhard; F Walcher; M Helm; M Kulla
Journal:  Unfallchirurg       Date:  2018-07       Impact factor: 1.000

2.  Observed versus expected mortality in pediatric patients intubated in the field with Glasgow Coma Scale scores < 9.

Authors:  Pedram Emami; Patrick Czorlich; Friederike S Fritzsche; Manfred Westphal; Johannes M Rueger; Rolf Lefering; Michael Hoffmann
Journal:  Eur J Trauma Emerg Surg       Date:  2019-01-10       Impact factor: 3.693

3.  Circulation first - the time has come to question the sequencing of care in the ABCs of trauma; an American Association for the Surgery of Trauma multicenter trial.

Authors:  Paula Ferrada; Rachael A Callcut; David J Skarupa; Therese M Duane; Alberto Garcia; Kenji Inaba; Desmond Khor; Vincent Anto; Jason Sperry; David Turay; Rachel M Nygaard; Martin A Schreiber; Toby Enniss; Michelle McNutt; Herb Phelan; Kira Smith; Forrest O Moore; Irene Tabas; Joseph Dubose
Journal:  World J Emerg Surg       Date:  2018-02-05       Impact factor: 5.469

4.  Determining optimal needle size for decompression of tension pneumothorax in children - a CT-based study.

Authors:  Georg Leonhard; Daniel Overhoff; Lucas Wessel; Tim Viergutz; Marcus Rudolph; Michael Schöler; Holger Haubenreisser; Tom Terboven
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2019-10-11       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.